Agios Pharmaceuticals Inc (AGIO)

Feb 21, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Down 6.0% in January - MarketBeat

Feb 21, 2025

Feb 20, 2025

Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 - The Manila Times

Feb 20, 2025

Feb 20, 2025

Why Agios Pharmaceuticals' (NASDAQ:AGIO) Earnings Are Weaker Than They Seem - Simply Wall St

Feb 20, 2025

Feb 20, 2025

Rare Disease Leader Agios Takes Center Stage at Major Healthcare ConferenceKey Details Inside - StockTitan

Feb 20, 2025

Feb 20, 2025

Gilbert Cisneros conducts multiple transactions in stocks including Agios Pharmaceuticals and Airbnb - MSN

Feb 20, 2025

Feb 19, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2024 Earnings Call Transcript - MSN

Feb 19, 2025

Feb 19, 2025

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded by StockNews.com to "Sell" - MarketBeat

Feb 19, 2025

Feb 17, 2025

Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues - MSN

Feb 17, 2025

Feb 17, 2025

Here's Why Agios Stock Plummeted More Than 20% on Monday - MSN

Feb 17, 2025

Feb 16, 2025

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates - MSN

Feb 16, 2025

Feb 15, 2025

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 15, 2025

Feb 15, 2025

Agios Pharmaceuticals price target lowered to $74 from $75 at Scotiabank - Yahoo Finance

Feb 15, 2025

Feb 15, 2025

Agios Pharmaceuticals announces board resignation - MSN

Feb 15, 2025

Feb 15, 2025

Long Term Trading Analysis for (AGIO) - Stock Traders Daily

Feb 15, 2025

Feb 14, 2025

Agios Pharmaceuticals: Liver Toxicity Issues May Threaten Thalassemia Approval (Rating Downgrade) - Seeking Alpha

Feb 14, 2025

Feb 14, 2025

Positive Phase III ACTIVATE-Kids study of Agios’ mitapivat - The Pharma Letter

Feb 14, 2025

Feb 14, 2025

Agios Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Feb 14, 2025

Feb 14, 2025

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlight - GuruFocus.com

Feb 14, 2025

Feb 14, 2025

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance

Feb 14, 2025

Feb 14, 2025

Agios Pharmaceuticals Inc (AGIO) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and ... By GuruFocus - Investing.com Canada

Feb 14, 2025

Feb 13, 2025

Agios Pharmaceuticals Earnings Call Highlights Growth & Pipeline Progress - TipRanks

Feb 13, 2025

Feb 13, 2025

Agios Pharmaceuticals targets multi-billion-dollar growth with Pyrukynd expansion in 2025 - MSN

Feb 13, 2025

Feb 13, 2025

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years - Benzinga

Feb 13, 2025

Feb 13, 2025

Agios Pharmaceuticals, Inc. Announces Resignation of David P. Schenkein, M.D from Board of Directors and Member of the Science and Technology Committee, Effective February 28, 2025 - Marketscreener.com

Feb 13, 2025

Feb 13, 2025

Research Analysts Offer Predictions for AGIO FY2024 Earnings - MarketBeat

Feb 13, 2025

Feb 13, 2025

Agios Pharmaceuticals Inc. (AGIO) reports earnings - Quartz

Feb 13, 2025

Feb 13, 2025

Agios Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 13, 2025

Feb 13, 2025

AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

Feb 13, 2025

Feb 13, 2025

Agios Pharmaceuticals announces board resignation By Investing.com - Investing.com Nigeria

Feb 13, 2025

Feb 13, 2025

Earnings call transcript: Agios Pharm Q4 2024 beats EPS forecast, stock rises - Investing.com UK

Feb 13, 2025

Feb 13, 2025

Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint - The Manila Times

Feb 13, 2025

Feb 13, 2025

Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times

Feb 13, 2025

Feb 13, 2025

Agios Pharma Board Member Announces Resignation - TipRanks

Feb 13, 2025

Feb 13, 2025

Clinical Trial Breakthrough: Agios' Blood Disorder Drug Outperforms Placebo in Rare Pediatric Disease - StockTitan

Feb 13, 2025

Feb 13, 2025

Rep. Gilbert Ray Cisneros, Jr. Buys Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock - Defense World

Feb 13, 2025

Feb 12, 2025

Agios Pharmaceuticals Q4 2024 Earnings Preview - MSN

Feb 12, 2025

Feb 12, 2025

Agios Pharmaceuticals price target lowered to $54 from $55 at BofA - Yahoo Finance

Feb 12, 2025

Feb 12, 2025

Agios Pharmaceuticals, Inc. (AGIO): A Cheap Biotech Stock to Invest In Now - Insider Monkey

Feb 12, 2025

Feb 12, 2025

10 Cheap Biotech Stocks to Invest in Now - Insider Monkey

Feb 12, 2025

Feb 11, 2025

Beta Thalassemia Treatment Market Size Report 2032 | Novartis, - openPR

Feb 11, 2025

Feb 08, 2025

Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results - MSN

Feb 08, 2025

Feb 06, 2025

Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart

Feb 06, 2025

Feb 06, 2025

Q4 Earnings Alert: Agios Pharmaceuticals Sets Critical Financial Update for Rare Disease Pipeline - StockTitan

Feb 06, 2025